Curran Terrie
SEC Form 4 insider trading activity
Curran Terrie has filed 3 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 28, 2026.
On the most recent filing, Curran Terrie is listed as Director at Arcutis Biotherapeutics, Inc. Inside the rolling window, Curran Terrie reported no open-market purchases and 2 open-market sales totaling $984K in ARQT. The largest disclosed transaction in the window is a sale of 38,200 ARQT shares on Aug 27, 2026, worth $956K.
Companies traded
Other insiders at ARQT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$984K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Curran Terrie made?
Curran Terrie has filed 3 SEC Form 4 filings (7 transaction rows) across 1 company since 2026.
Which companies does Curran Terrie trade?
Curran Terrie has filed SEC Form 4 disclosures for 1 company, including ARQT.
When was Curran Terrie's most recent SEC Form 4 filing?
Curran Terrie's most recent SEC Form 4 filing on Tracefour is dated Aug 28, 2026.
What is Curran Terrie's total buy and sell value in the current window?
Inside the rolling retention window, Curran Terrie bought $0 and sold $984K based on SEC Form 4 filings.
What was Curran Terrie's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 38,200 ARQT shares on 2026-08-27, worth $956K, per SEC Form 4 filings.